Published in J Hematol Oncol on March 26, 2010
Hypersensitivity reactions associated with platinum antineoplastic agents: a systematic review. Met Based Drugs (2010) 1.18
The behavior of matrix metalloproteinases and their inhibitors in colorectal cancer. Int J Mol Sci (2012) 0.96
Management of hypersensitivity to platinum- and taxane-based chemotherapy: cepo review and clinical recommendations. Curr Oncol (2014) 0.90
Oxaliplatin-induced acute-onset thrombocytopenia and hemorrhage: Case report and review of the literature. Oncol Lett (2012) 0.80
Oxaliplatin-induced severe anaphylactic reactions in metastatic colorectal cancer: case series analysis. World J Gastroenterol (2012) 0.79
Oxaliplatin-Induced Immune-Mediated Thrombocytopenia: A Case Report. Cancer Res Treat (2014) 0.75
A 39-year-old female patient with metastatic rectal cancer develops thrombocytopenia. Gastrointest Cancer Res (2014) 0.75
A case of oxaliplatin-induced immune-mediated thrombocytopenia. Blood Res (2014) 0.75
Baseline thrombocytopenia complicated by recurrent episodes of transient severe thrombocytopenia following infections in an adult woman with a non involuting congenital hemangioma - a case report. BMC Hematol (2013) 0.75
Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med (2004) 18.93
A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol (2003) 12.24
Drug-induced immune thrombocytopenia. N Engl J Med (2007) 5.61
Hypersensitivity reactions to oxaliplatin: experience in a single institute. Ann Oncol (2005) 1.77
Immune-mediated thrombocytopenia resulting from sensitivity to oxaliplatin. Am J Hematol (2006) 1.43
Allergic-type reactions to oxaliplatin: retrospective analysis of 42 patients. Eur J Cancer (2005) 1.14
Hypersensitivity reactions related to oxaliplatin (OHP). Br J Cancer (2003) 1.11
Hypersensitivity reactions to oxaliplatin and the application of a desensitization protocol. Oncologist (2004) 1.10
Oxaliplatin-induced haematological emergency with an immediate severe thrombocytopenia and haemolysis. Acta Oncol (2001) 1.08
Oxaliplatin-induced immune pancytopenia. Transfusion (2005) 1.07
Oxaliplatin-induced Evan's syndrome. Br J Cancer (2001) 1.04
Fatal thrombocytopenia after oxaliplatin-based chemotherapy. Anticancer Res (2008) 1.01
Hemolytic uremic syndrome following the infusion of oxaliplatin: case report. BMC Clin Pharmacol (2006) 1.00
Oxaliplatin-induced acute-onset thrombocytopenia, hemorrhage and hemolysis. Oncology (2004) 0.95
Oxaliplatin-induced immune thrombocytopenia. Gastroenterol Clin Biol (2006) 0.94
Hypersensitivity Reactions to oxaliplatin: incidence and management. Oncology (Williston Park) (2004) 0.92
Oxaliplatin-induced hemolytic anemia during adjuvant treatment of a patient with colon cancer: a case report. Anticancer Drugs (2007) 0.90
Oxaliplatin-induced immune hemolytic anemia: a case report and review of the literature. Anticancer Drugs (2007) 0.90
Irinotecan-induced immune thrombocytopenia. Ann Oncol (1998) 0.89
Sudden-onset thrombocytopenia with oxaliplatin. Ann Intern Med (2003) 0.89
Severe anaphylactic reactions in patients receiving oxaliplatin therapy: a rare but potentially fatal complication. Support Care Cancer (2006) 0.89
Life-threatening oxaliplatin-induced acute thrombocytopenia, hemolysis and bleeding: a case report. Acta Oncol (2008) 0.82
Oxaliplatin-induced immune mediated thrombocytopenia. Cancer Chemother Pharmacol (2008) 0.82
Oxaliplatin-induced acute renal failure presenting clinically as thrombotic microangiopathy: think of acute tubular necrosis. NDT Plus (2009) 0.82
Oxaliplatin-induced immune thrombocytopenia: another cumulative dose-dependent side effect? Clin Colorectal Cancer (2009) 0.81
Platelet CD36 links hyperlipidemia, oxidant stress and a prothrombotic phenotype. Nat Med (2007) 4.11
Vancomycin-induced immune thrombocytopenia. N Engl J Med (2007) 3.35
Acute thrombocytopenia after treatment with tirofiban or eptifibatide is associated with antibodies specific for ligand-occupied GPIIb/IIIa. Blood (2002) 2.37
Enhanced activation of STAT pathways and overexpression of survivin confer resistance to FLT3 inhibitors and could be therapeutic targets in AML. Blood (2009) 2.14
The neutrophil alloantigen HNA-3a (5b) is located on choline transporter-like protein 2 and appears to be encoded by an R>Q154 amino acid substitution. Blood (2009) 2.02
Identifying drugs that cause acute thrombocytopenia: an analysis using 3 distinct methods. Blood (2010) 1.76
Patients with quinine-induced immune thrombocytopenia have both "drug-dependent" and "drug-specific" antibodies. Blood (2006) 1.73
Heparin-induced thrombocytopenia associated with fondaparinux. N Engl J Med (2007) 1.57
Antibodies causing thrombocytopenia in patients treated with RGD-mimetic platelet inhibitors recognize ligand-specific conformers of αIIb/β3 integrin. Blood (2012) 1.46
Phase I and biomarker study of ABT-869, a multiple receptor tyrosine kinase inhibitor, in patients with refractory solid malignancies. J Clin Oncol (2009) 1.46
Acute thrombocytopenia in patients treated with the oral glycoprotein IIb/IIIa inhibitors xemilofiban and orbofiban: evidence for an immune etiology. Thromb Haemost (2002) 1.44
Immune-mediated thrombocytopenia resulting from sensitivity to oxaliplatin. Am J Hematol (2006) 1.43
Drug-induced thrombocytopenia: pathogenesis, evaluation, and management. Hematology Am Soc Hematol Educ Program (2009) 1.42
Extracellular DNA traps are associated with the pathogenesis of TRALI in humans and mice. Blood (2012) 1.42
The slow-releasing hydrogen sulfide donor, GYY4137, exhibits novel anti-cancer effects in vitro and in vivo. PLoS One (2011) 1.37
Neonatal alloimmune thrombocytopenia: pathogenesis, diagnosis and management. Br J Haematol (2013) 1.33
Clinicopathologic features of agranulocytosis in the setting of levamisole-tainted cocaine. Am J Clin Pathol (2010) 1.31
Novel targeted therapeutics: inhibitors of MDM2, ALK and PARP. J Hematol Oncol (2011) 1.31
Recent advances in gastrointestinal oncology--updates and insights from the 2009 annual meeting of the American society of clinical oncology. J Hematol Oncol (2010) 1.30
Fine specificity of drug-dependent antibodies reactive with a restricted domain of platelet GPIIIA. Blood (2007) 1.30
Eptifibatide-induced thrombocytopenia and thrombosis in humans require FcgammaRIIa and the integrin beta3 cytoplasmic domain. J Clin Invest (2009) 1.24
Exosome removal as a therapeutic adjuvant in cancer. J Transl Med (2012) 1.24
New platelet glycoprotein polymorphisms causing maternal immunization and neonatal alloimmune thrombocytopenia. Transfusion (2011) 1.21
Recurrent acute thrombocytopenia in the hospitalized patient: sepsis, DIC, HIT, or antibiotic-induced thrombocytopenia. Am J Hematol (2010) 1.18
Epstein-Barr virus-associated posttransplantation lymphoproliferative disorder after high-dose immunosuppressive therapy and autologous CD34-selected hematopoietic stem cell transplantation for severe autoimmune diseases. Biol Blood Marrow Transplant (2003) 1.18
Thrombocytopenia after second exposure to abciximab is caused by antibodies that recognize abciximab-coated platelets. Blood (2002) 1.12
Drug-dependent clearance of human platelets in the NOD/scid mouse by antibodies from patients with drug-induced immune thrombocytopenia. Blood (2010) 1.11
Neonatal alloimmune thrombocytopenia associated with maternal-fetal incompatibility for blood group B. Transfusion (2007) 1.10
Platelet factor 4 differentially modulates CD4+CD25+ (regulatory) versus CD4+CD25- (nonregulatory) T cells. J Immunol (2005) 1.06
Human platelet antigen-specific alloantibodies implicated in 1162 cases of neonatal alloimmune thrombocytopenia. Transfusion (2004) 1.05
Hemolysis and hyperhomocysteinemia caused by cobalamin deficiency: three case reports and review of the literature. J Hematol Oncol (2008) 1.04
Inhibition of CD44 expression in hepatocellular carcinoma cells enhances apoptosis, chemosensitivity, and reduces tumorigenesis and invasion. Cancer Chemother Pharmacol (2008) 1.01
Maternal alloimmunization against the rare platelet-specific antigen HPA-9b (Max a) is an important cause of neonatal alloimmune thrombocytopenia. Transfusion (2005) 1.01
Quinine/quinidine-induced thrombocytopenia: a great imitator. Arch Intern Med (2004) 1.00
Quinine-dependent, platelet-reactive monoclonals mimic antibodies found in patients with quinine-induced immune thrombocytopenia. Blood (2008) 1.00
Practices, attitudes, and beliefs associated with complementary and alternative medicine (CAM) use among cancer patients. Integr Cancer Ther (2012) 0.99
Updates in Gastrointestinal Oncology - insights from the 2008 44th annual meeting of the American Society of Clinical Oncology. J Hematol Oncol (2009) 0.97
ABT-869, a promising multi-targeted tyrosine kinase inhibitor: from bench to bedside. J Hematol Oncol (2009) 0.97
Mass spectrometric studies on epigenetic interaction networks in cell differentiation. J Biol Chem (2011) 0.96
PRL-3, a metastasis associated tyrosine phosphatase, is involved in FLT3-ITD signaling and implicated in anti-AML therapy. PLoS One (2011) 0.96
Pathological complete response after neoadjuvant chemotherapy with trastuzumab-containing regimen in gastric cancer: a case report. J Hematol Oncol (2010) 0.95
Pancytopenia associated with clonazepam. J Hematol Oncol (2010) 0.95
Neonatal alloimmune neutropenia attributed to maternal immunoglobulin G antibodies against the neutrophil alloantigen HNA-1c (SH): a report of five cases. Transfusion (2005) 0.94
HNA-3a-specific antibodies recognize choline transporter-like protein-2 peptides containing arginine, but not glutamine at Position 154. Transfusion (2011) 0.93
ABT-869, a multi-targeted tyrosine kinase inhibitor, in combination with rapamycin is effective for subcutaneous hepatocellular carcinoma xenograft. J Hepatol (2008) 0.91
Cleavage of misfolded nuclear receptor corepressor confers resistance to unfolded protein response-induced apoptosis. Cancer Res (2006) 0.90
Expression of the epigenetic factor BORIS (CTCFL) in the human genome. J Transl Med (2011) 0.90
Deprivation of arginine by recombinant human arginase in prostate cancer cells. J Hematol Oncol (2012) 0.90
Drug-induced thrombocytopenia in children. Pediatr Blood Cancer (2013) 0.90
Isoimmunization against CD36 (glycoprotein IV): description of four cases of neonatal isoimmune thrombocytopenia and brief review of the literature. Transfusion (2002) 0.89
A modified regimen of pegylated liposomal doxorubicin, bortezomib and dexamethasone (DVD) is effective and well tolerated for previously untreated multiple myeloma patients. Br J Haematol (2011) 0.89
Gastric bleeding due to graft-vs-host disease: discrepancy between endoscopic and histologic assessment. Am J Clin Pathol (2004) 0.89
Prevalence and clinical significance of low-avidity HPA-1a antibodies in women exposed to HPA-1a during pregnancy. Transfusion (2012) 0.88
Determinants of sensitivity to DZNep induced apoptosis in multiple myeloma cells. PLoS One (2011) 0.87
Synergistic antileukemia effect of genistein and chemotherapy in mouse xenograft model and potential mechanism through MAPK signaling. Exp Hematol (2007) 0.87
Neonatal neutropenia and bacterial sepsis associated with placental transfer of maternal neutrophil-specific autoantibodies. Transfusion (2004) 0.87
Drug-induced thrombocytopenia and thrombosis: evidence from patients receiving an oral glycoprotein IIb/IIIa inhibitor in the Orbofiban in Patients with Unstable coronary Syndromes- (OPUS-TIMI 16) trial. J Thromb Thrombolysis (2006) 0.85
Combination therapy of recurrent prostate cancer with the proteasome inhibitor bortezomib plus hormone blockade. Cancer Biol Ther (2011) 0.85
Clinico-pathologic relevance of Survivin splice variant expression in cancer. Cancer Lett (2013) 0.84
B-cell tolerance regulates production of antibodies causing heparin-induced thrombocytopenia. Blood (2013) 0.84
Progressive loss of epidermal growth factor receptor in a subpopulation of breast cancers: implications in target-directed therapeutics. Mol Cancer Ther (2007) 0.84
Acute thrombocytopenia caused by sensitivity to the glucuronide conjugate of acetaminophen. Blood (2007) 0.84
Therapeutic targeting of nuclear receptor corepressor misfolding in acute promyelocytic leukemia cells with genistein. Mol Cancer Ther (2007) 0.84
Clinical significance of E2F1 protein expression in non-small cell lung cancer. Exp Hematol Oncol (2012) 0.84
Clinical implications of microsomal prostaglandin e synthase-1 overexpression in human non-small-cell lung cancer. Ann Surg Oncol (2006) 0.83
In vivo activity of ABT-869, a multi-target kinase inhibitor, against acute myeloid leukemia with wild-type FLT3 receptor. Leuk Res (2007) 0.83
Time-dependent dynamic mobilization of circulating progenitor cells during percutaneous coronary intervention in diabetics. Int J Cardiol (2009) 0.82
Autologous stromal vascular fraction therapy for rheumatoid arthritis: rationale and clinical safety. Int Arch Med (2012) 0.82
The significance of detecting WT1 expression in childhood acute leukemias. Pediatr Hematol Oncol (2010) 0.82
Determination of neutrophil antigen HNA-3a and HNA-3b genotype frequencies in six racial groups by high-throughput 5' exonuclease assay. Transfusion (2012) 0.82
Drug-induced thrombotic microangiopathy: Experience of the Oklahoma Registry and the BloodCenter of Wisconsin. Am J Hematol (2015) 0.81
Acquired Glanzmann's thrombasthenia as part of multiple-autoantibody syndrome in a pediatric heart transplant patient. J Pediatr (2004) 0.81
Thrombocytopenia resulting from sensitivity to GPIIb-IIIa inhibitors. Semin Thromb Hemost (2004) 0.81
Intravenous ascorbic acid to prevent and treat cancer-associated sepsis? J Transl Med (2011) 0.81
Oxaliplatin-induced immune thrombocytopenia: another cumulative dose-dependent side effect? Clin Colorectal Cancer (2009) 0.81
A point mutation in the EGF-4 domain of β(3) integrin is responsible for the formation of the Sec(a) platelet alloantigen and affects receptor function. Thromb Haemost (2011) 0.80
Potential role of platelet-derived growth factor receptor inhibition using imatinib in combination with docetaxel in the treatment of recurrent non-small cell lung cancer. J Thorac Oncol (2011) 0.80
Full-length recombinant choline transporter-like protein 2 containing arginine 154 reconstitutes the epitope recognized by HNA-3a antibodies. Transfusion (2011) 0.80
Expression of ABH antigens on platelets. Blood (2006) 0.79
Protamine-induced immune thrombocytopenia. Transfusion (2013) 0.79
Detection of antibodies against human platelet antigens 15a and 15b by using a cell line panel. Br J Haematol (2010) 0.79